P
Plexium
A drug development startup that leverages techniques from various physical-science and computational disciplines
About Plexium
Plexium is a biotech startup that operates in the field of targeted protein degradation (TPD), a promising area of drug discovery. The company's primary focus is on the development of next-generation TPD drugs that can target and degrade disease-causing proteins in the body. These drugs have potential applications in a wide range of therapeutic areas, including cancer and other serious diseases.
Plexium's unique selling point is its proprietary high-throughput cell-based screening technology. This technology allows the company to rapidly test and identify compounds that can degrade target proteins in a disease-relevant environment. This accelerates the drug discovery process and increases the chances of finding effective treatments.
The company's business model revolves around the development and commercialization of its TPD drugs. Plexium generates revenue through the sale of these drugs once they have been approved by regulatory bodies. Additionally, the company also partners with other biotech and pharmaceutical companies to develop and commercialize new drugs, providing another source of income.
Plexium's clients are primarily patients suffering from diseases that can be treated with TPD drugs. However, the company also serves the broader medical community by providing new treatment options and contributing to the advancement of medical science.
In summary, Plexium is a pioneering biotech company that is pushing the boundaries of targeted protein degradation to improve lives. Its unique technology and innovative approach to drug discovery make it a promising player in the biotech industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- San Diego, United States
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2025 | $60M | $510M | Undisclosed | ↗ |
| LATE VCOther financing | Feb 2022 | $102M | $408M | CRV · Pivotal Life Sciences · Neotribe · M Ventures | ↗ |
Growth signals
Latest recorded traffic for Plexium is 5.7K monthly website visits, up 111.1% over the last three months. Plexium's team declined 29.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
The Column Group
M Ventures
Series B and later9 investors entered at this stage
Lux Capital
Pivotal Life Sciences
Neotribe
TCGX
SoftBank
Pappas Capital
BVF Partners
RA Capital Management
Surveyor Capital
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Plexium on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Plexium’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.